Become A Featured Company

DigiPath Labs Reports New Strains Reach >30% Cannabinoid Content

Ryan Allway

March 8th, 2016

News, Top News

DigiPath Inc. (OTCQB: DIGP), a provider of reliable testing, education and training, and unbiased news coverage to the cannabis industry, recently announced that it reached a new plateau in certified cannabinoid cannabis. After looking at over 600 samples, the company certified
Headcheese and True OG strains at 35.1% and 37.1% total cannabinoid content. This is significant not only in the Las Vegas market but throughout the country.

These strains were tested on behalf of Polaris MMJ and will be available through preferred Las Vegas medical dispensaries in the near future. Polaris MMJ is an established provider of premium cannabis and infused products that use meticulous cultivation methods that provide each plant the necessary attention for optimal results. DigiPath Labs has been working with the company to certify the products before they hit consumer shelves.

Read the entire press release here:

DigiPath Inc. (DIGP), an independent cannabis testing and media firm, recently tested some strains of cannabis unlike anything they’ve seen thus far in their Las Vegas lab. This week DigiPath Labs reached a new plateau in certified cannabinoid content.  After analyzing over six hundred cannabis flower samples, two separate cured cannabis flower samples were certified at 35.1% and 37.5% total cannabinoid content.  The two strains in question, Headcheese and True OG, are new arrivals to the Las Vegas medical marijuana community through the cultivating efforts of Polaris MMJ.  Cannabinoid levels coming in over 30% are unique, not just in Vegas but across the country.

A closer look at the breakdown of cannabinoids in these two strains reveals two unique profiles.  The hybrid Headcheese strain produced not only a remarkable 31.35% THCA but an even lesser seen level of 2.46% CBGA, the chemical precursor molecule of both THCA and CBDA; while True OG came in with a whopping 35.9% THCA.  From the terpenoid profiles, we observed high levels of myrcene (think mango, lemongrass, relaxed, happy) and isopulegol (the precursor to menthol) in the Headcheese strain while the True OG strain also had notable myrcene, limonene (love lemon) and linalool (anti-epileptic, lavender).

“Headcheese, a sativa-indica hybrid strain has attracted followings across the country due to its impressive THCA levels attributed to its astonishing analgesic benefits to alleviate migraines, inflammation, spasms and insomnia,” said Dr. Cindy Orser, Digipath Labs, chief science officer.   “The cured yellow-green brain-shaped flower buds have a lemon, pine, and cheese aroma leaving an earthy not fruity taste.  The cheese-head effects are reportedly a total mind body experience, both relaxing and euphoric.”

True OG is reported to be an indica strain from Southern California with a pungent, earthy citrus note.  It is a potent strain capable of offering up a long-standing focused head high that alleviates insomnia well.  The sedative, analgesic medicinal effects are notable.

Look for both of these Polaris MMJ exclusive noteworthy and potent strains at your preferred LAS VEGAS medical marijuana dispensary soon.

About Digipath

DigiPath, Inc., supports the cannabis industry’s best practices for reliable testing, education, and training, and brings unbiased cannabis news coverage to the nation. DigiPath’s two business units are DigiPath Labs and TNM News Corp. For more information, go to www.digipath.com.

About Polaris MMJ

Polaris MMJ is an established provider of premium cannabis and infused products based in Nevada.  Polaris MMJ is a boutique outfit using meticulous cultivation methods that give each and every plant the attention necessary for optimal results. The founders, Peter Ishak, Lee McCue and Jim Switzer have been relentlessly focused on enhancing the highest cannabinoid and terpenoid profiles in the world. In addition to THC, Polaris MMJ has been diligently developing strands that are extremely high in CBG which is known to greatly help with chronic pain, intra-ocular pressure, and depression.  Polaris MMJ has recently emerged as the leader in THC levels exceeding thirty-five percent and CBG levels reaching close to four percent. The team pledges their commitment to pushing the envelope in profile development while maintaining the quality and consistency desired for patients in need. To learn more about Polaris MMJ please email: contact@polariswellnesscenter.com or call 725-222-4201.

Information about Forward-Looking Statements

This press release contains “forward-looking statements” that include information relating to future events, and future financial and operating performance. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company’s need for additional funding, the demand for the Company’s products, governmental regulation of the cannabis industry, the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting DigiPath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading